Verona Pharma Unveils Q2 2023 Results: Here’s What You Need to Know

Verona Pharma plc (Nasdaq: VRNA), a clinical-stage biopharmaceutical company dedicated to advancements in respiratory disease treatments, will reveal its financial results for the second quarter ended June 30, 2023 and provide an insightful corporate update during an investment community conference call on Thursday, August 3, 2023 at 9:00 a.m. EDT / 2:00 p.m. BST. Stay tuned to hear about the progress the Company continues to make in the development of innovative solutions for respiratory-related health concerns.

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company striving to make a real difference for patients suffering from chronic respiratory diseases. With unmet medical needs in this field, they are researching and developing innovative therapies – particularly the potential of a compound called ensifentrine. This single compound has the potential to both dilate the bronchials and offer anti-inflammatory effects in one.

Thanks to the ENHANCE clinical program, a significant improvement in lungfunction was seen in patients, while a reduced rate and risk of COPD exacerbations has been observed in the pooled analysis.

Consequently, they submitted an NDA to the FDA for their therapy for COPD maintenance in the second quarter of 2023. Furthermore, two additional formulations of ensifentrine have been evaluated in Phase 2 studies for other respiratory diseases, like cystic fibrosis and asthma. All of this will hopefully give hope to millions who are living with respiratory diseases.

Leave a Comment